Time to first moderate or severe COPD exacerbation with tezepelumab (COURSE) - Vienna 2024

Airway diseases therapeutics: novel research studies

Chair(s): Manali Mukherjee, Alexander Mathioudakis

Session type: Oral presentation

Time to first moderate or severe COPD exacerbation with tezepelumab (COURSE)

Dave Singh

EVENTS HOME

Previous presentation

Next presentation

Session content

Air trapping measured at HRCT predicts benralizumab response better than blood eosinophil count in severe asthma

Arnaud Bourdin

Replay

Abstract

Slides

Time to first moderate or severe COPD exacerbation with tezepelumab (COURSE)

Dave Singh

Replay

Poster

Abstract

Slides

Late Breaking Abstract - Efficacy of high- and low-dose rilzabrutinib from a phase 2 study

Ian Douglas Pavord

Replay

Poster

Abstract

Slides

Anti-inflammatory effects of PDE3/4 inhibitor ensifentrine in peripheral blood mononuclear cells from COPD patients

Simon Lea

Replay

Abstract

Slides

KN-002 reduces fractional exhaled nitric oxide in moderate to severe asthma

Dave Singh

Replay

Poster

Abstract

Slides

The effects of inhaled corticosteroids on healthy airways

Timothy Hinks

Replay

Poster

Abstract

Slides

Inhaled Corticosteroid Treatment Reduces Airway Adaptive Immune Cells in Asthma

Daisy Bornesund

Replay

Poster

Abstract

Slides

Impact of early transient increase in eosinophils in patients with moderate-to-severe asthma on the long-term efficacy of dupilumab in TRAVERSE

Ian Douglas Pavord

Replay

Poster

Abstract

Slides

Ensifentrine improved lung function and reduced moderate/severe exacerbation rate and risk in patients with COPD regardless of chronic bronchitis history

Jadwiga Wedzicha

Replay

Poster

Abstract

Slides

Improved lung function and asthma control observed with rademikibart in patients with moderate-to-severe asthma

Raul Collazo

Replay

Abstract

Slides

Discussion and Q&A

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}